Surgery Partners Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Surgery Partners wird ein jährliches Gewinn- und Umsatzwachstum von 61.5% bzw. 9.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 64.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.7% betragen.
Wichtige Informationen
60.9%
Wachstumsrate der Gewinne
60.0%
EPS-Wachstumsrate
Healthcare Gewinnwachstum | 19.3% |
Wachstumsrate der Einnahmen | 9.3% |
Zukünftige Eigenkapitalrendite | 7.3% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 16 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward
Jul 25Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden
Jul 13Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement
Jun 21We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now
May 31Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion
Apr 24Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall
Mar 18Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Feb 27The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)
Dec 19Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)
Oct 26Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?
Sep 17Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?
Aug 26The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising
Jul 21Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit
Jun 15A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)
May 26There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital
Apr 14Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet
Mar 24Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 24We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt
Sep 26The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence
Aug 15Surgery Partners GAAP EPS of -$0.21 misses by $0.07, revenue of $615.4M misses by $3.61M
Aug 02Surgery Partners And Alternative Near Cap-Gain Portfolio Wealth Builders
Jul 02Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Jun 27Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?
Mar 27Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 3,680 | 175 | 339 | 346 | 7 |
12/31/2025 | 3,373 | 143 | 264 | 376 | 12 |
12/31/2024 | 3,086 | 59 | 172 | 300 | 11 |
6/30/2024 | 2,889 | -34 | 204 | 291 | N/A |
3/31/2024 | 2,795 | 1 | 175 | 260 | N/A |
12/31/2023 | 2,743 | -12 | 205 | 294 | N/A |
9/30/2023 | 2,715 | -34 | 147 | 238 | N/A |
6/30/2023 | 2,662 | -54 | 73 | 164 | N/A |
3/31/2023 | 2,609 | -92 | 67 | 154 | N/A |
12/31/2022 | 2,539 | -55 | 78 | 159 | N/A |
9/30/2022 | 2,442 | -31 | 99 | 171 | N/A |
6/30/2022 | 2,381 | -29 | 86 | 157 | N/A |
3/31/2022 | 2,309 | -38 | 55 | 117 | N/A |
12/31/2021 | 2,225 | -81 | 30 | 87 | N/A |
9/30/2021 | 2,163 | -86 | 18 | 76 | N/A |
6/30/2021 | 2,100 | -135 | 37 | 88 | N/A |
3/31/2021 | 1,932 | -150 | 222 | 268 | N/A |
12/31/2020 | 1,860 | -156 | 204 | 247 | N/A |
9/30/2020 | 1,829 | -179 | 212 | 263 | N/A |
6/30/2020 | 1,785 | -132 | 232 | 293 | N/A |
3/31/2020 | 1,856 | -119 | 65 | 138 | N/A |
12/31/2019 | 1,831 | -110 | 56 | 130 | N/A |
9/30/2019 | 1,805 | -238 | 86 | 150 | N/A |
6/30/2019 | 1,786 | -243 | 67 | 122 | N/A |
3/31/2019 | 1,777 | -241 | 94 | 135 | N/A |
12/31/2018 | 1,772 | -238 | 105 | 145 | N/A |
9/30/2018 | 1,732 | -122 | 118 | 154 | N/A |
6/30/2018 | 1,597 | -125 | 104 | 134 | N/A |
3/31/2018 | 1,443 | -102 | N/A | 116 | N/A |
12/31/2017 | 1,312 | -79 | N/A | 121 | N/A |
9/30/2017 | 1,159 | -22 | N/A | 99 | N/A |
6/30/2017 | 1,135 | 7 | N/A | 108 | N/A |
3/31/2017 | 1,139 | 14 | N/A | 135 | N/A |
12/31/2016 | 1,121 | 9 | N/A | 125 | N/A |
9/30/2016 | 1,079 | 9 | N/A | 117 | N/A |
6/30/2016 | 1,039 | 9 | N/A | 128 | N/A |
3/31/2016 | 981 | 1 | N/A | 100 | N/A |
12/31/2015 | 936 | 1 | N/A | 84 | N/A |
9/30/2015 | 855 | -70 | N/A | 53 | N/A |
6/30/2015 | 696 | -73 | N/A | 38 | N/A |
3/31/2015 | 544 | -69 | N/A | 27 | N/A |
12/31/2014 | 394 | -66 | N/A | 22 | N/A |
12/31/2013 | 279 | -9 | N/A | 49 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SGRY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.5%).
Ertrag vs. Markt: SGRY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: SGRY wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: SGRYDie Einnahmen des Unternehmens (9.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: SGRYDie Einnahmen des Unternehmens (9.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: SGRYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6.4%).